Could This Beaten-Down Biotech Stock Be the Next Buyout Target?

·5-min read
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?

What do AbbVie, Bristol Myers Squibb, and AstraZeneca all have in common? With that in mind, let's look at a biotech company that could become a buyout target within the next couple of years, Bluebird Bio (NASDAQ: BLUE). Both the broader market and the biotech industry -- as measured by the SPDR S&P Biotech Index -- have performed substantially better.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting